Spyre Therapeutics, Inc. (SYRE) earnings
SYRE earnings moved a median of -0.93% by the close. Quarterly and annual SYRE reports and results, each read against the price at its own news timestamp. Back to the SYRE overview →
25 measured SYRE earnings events.
Where these SYRE earnings landedvs 25 measured SYRE earnings reactions
| Middle 50% of SYRE earnings reactions | -3.20% to +1.07% |
|---|---|
| Median reaction (to close) | -0.93% |
| Measured reactions | 25 |
Point-in-time · zero look-ahead
Half of the 25 SYRE earnings events with a measured close landed between -3.20% and +1.07%; 32% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Spyre Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | -1.42% | -0.96% | |
| Spyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update | Press release | -1.42% | -0.96% | |
| Form 10-Q Spyre Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | +2.05% | -0.56% | |
| Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | +2.05% | -0.56% | |
| Form 10-Q Spyre Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | +1.60% | +1.07% | |
| Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | +1.60% | +1.07% | |
| Form 10-K Spyre Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | +2.25% | +14.25% | |
| Form 10-Q Spyre Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | -2.18% | -2.23% | |
| Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | -2.18% | -2.23% | |
| Form 10-Q Spyre Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | -0.30% | -5.45% | |
| Form 10-Q Spyre Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | +3.77% | +4.14% | |
| Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update | Press release | +3.77% | +4.14% | |
| Form 10-K Spyre Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | +1.10% | +5.40% | |
| Form 10-K/A Spyre Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | -1.58% | -3.20% | |
| Form 10-Q/A Spyre Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | -1.58% | -3.20% | |
| Form 10-Q/A Spyre Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | -1.58% | -3.20% | |
| Form 10-Q/A Spyre Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | -1.58% | -3.20% | |
| Form 10-Q Spyre Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | +1.62% | +10.33% | |
| Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update | Press release | +1.62% | +10.33% | |
| Form 10-Q Spyre Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | -3.69% | -0.75% | |
| Spyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update | Press release | -3.69% | -0.75% | |
| Form 10-Q Spyre Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | -4.67% | -4.42% | |
| Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update | Press release | -4.67% | -4.42% | |
| Form 10-K/A Spyre Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | +2.68% | -0.93% | |
| Form 10-K Spyre Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | +2.68% | -0.93% |
Keep exploring
More SYRE: analyst actions → · SEC filings → · SYRE overview →